ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

About this update from Imagenebio, Inc.

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced management participation in fourth quarter investor conferences. 2025 Stifel Healthcare Conference Fireside Chat: Thursday, November 13, 9:20am EST New York, NY Piper Sander 37 th Annual Healthcare Conference Fireside Chat: Thursday, December 4, 10:00am EST New York, NY To access the live webcasts or subsequent archived recordings of the presentation and fireside chat, please visit the ImageneBio IR Site . About ImageneBio, Inc. ImageneBio is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The company’s lead asset, IMG-007, is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of IMG-007 in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. For more information, please visit  www.imagenebio.com . Investor and Media Contact: [email protected]

View stock analysis, news, and events for Imagenebio, Inc.